CD14 and COVID-19: Thus, in COVID-19 patients, GM-CSF potentially links the severe-pulmonary-syndrome-initiating capacity of pathogenic Th1 cells (GM-CSF+IFN-γ+) with the inflammatory signature of monocytes (CD14+CD16+ with high expression of IL-6) and their progeny.